Toronto, Ontario–(Newsfile Corp. – April 26, 2021) – Embark Health Inc. (“Embark” or the “Company”) has announced that Bruce Dawson-Scully, Founder & Executive Director, will step into the role of Chief Executive Officer effective April 26, 2021.

“We wish Dr. Luc C. Duchesne all the best and thank him for his contributions in accelerating the team’s momentum in driving the business forward,” said Bruce Dawson-Scully. “The strategic accomplishments the Company made with Luc throughout his tenure are significant, including the receipt of Embark’s cannabis processing license from Health Canada in conjunction with the receipt of the sales amendment license, operationalizing the Delta Facility, receipt of CRA license, building intellectual property, and continuing to foster our innovation pipeline through the acquisition of Axiomm Technologies.”

Dr. Luc C. Duchesne will remain in a consultative position with Embark continuing to provide support and expertise related to scientific initiatives of the Company. He will also liaise with Health Canada on behalf of Embark regarding regulatory affairs.

Along with Dr. Duchesne’s resignation as CEO, he has effectively resigned from the board of directors.

Bruce Dawson-Scully, a founding member of Embark, will provide leadership, direction, and guidance to the Company. As an already active member of the leadership team, continuity in the office of the CEO is uninterrupted. Bruce’s previous experience as CEO of a listed company and executing a go-public transaction will lend itself well to the demands of the role.

Bruce added, “We continue to move forward to execute on our strategy of going public in Q3 2021 and deliver on next generation cannabis 2.0 product offerings to the adult-use and medical-use markets, in addition to B2B contract manufacturing and white labelling service. I look forward to seeing the continued success of the Company.”

About Embark Health Inc.

Embark Health Inc. is a leader in solventless cannabis extraction, with a focus on the formulation and production of advanced 2.0 products for the B2B, medical, and adult-use markets. Embark continues to be at the forefront of production of concentrate products including bubble hash, traditional pressed hash, rosin, and dry sift. Building on Embark’s strength in innovation and creating industry-leading Cannabis 2.0 products, it recently announced new product offerings through its proprietary ground-breaking Embark Nano technology. The new suite of products coming to market include cannabis-infused beverages, topicals, edibles and water-soluble powders.

Embark-managed brands of next generation 2.0 products include The Hank Co. and The Hazel Co. under its line of solventless products, and, Distilled + Infused and Meridian under its line of beverage and topical products that utilizes the Embark Nano Technology.

It is Embark’s mandate to pursue best-in-class production processes resulting in premium quality commercial and consumer extraction products. Embark Health Inc. is dedicated to unleashing the full potential of the cannabis plant through scientific approaches to extraction and the production of quality products to enhance everyday life. For more information, please visit www.embarkhealthinc.com.

Investor Relations Contact:
[email protected]

FORWARD LOOKING STATEMENTS

This news release contains “forward-looking information” within the meaning of applicable securities laws including statements regarding the ability to leverage its existing Cannabis 2.0 products for the Canadian market, access to future markets, Embark’s ability to increase production and offer new products and services following receipt of applicable licences, the continued business-to-business activities of Embark, and the effects of the aforementioned activities on the operational and financial condition of Embark. Although Embark believes in light of the estimates by management, current conditions and expected future developments and other factors, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them. Accordingly, Embark can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, changes in economic conditions or financial markets; regulatory delays; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect our forward-looking information. The statements in this press release are made as of the date of this release. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company.

NOT FOR DISTRIBUTION TO US NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/81798